Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia 19Leukemia, Myeloid, Chronic-Phase 16Breast Neoplasms 11Neoplasm Metastasis 10Leukemia, Myeloid, Acute 8Blast Crisis 8Prostatic Neoplasms 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Recurrence 5Pancreatic Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Melanoma 4Gliosarcoma 4Glioblastoma 4Rectal Neoplasms 3Philadelphia Chromosome 3Lung Neoplasms 3Glioma 3Gastrointestinal Stromal Tumors 3Colorectal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Sarcoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2

Interventions

Temozolomide 45Radiotherapy 16Carboplatin 15Irinotecan 12Carmustine 12Bevacizumab 12Filgrastim 10Vincristine 9Surgical Procedures, Operative 9Magnetic Resonance Spectroscopy 9Procarbazine 7Peripheral Blood Stem Cell Transplantation 6Imatinib Mesylate 6Erlotinib Hydrochloride 6temsirolimus 5sargramostim 5O(6)-benzylguanine 5Lomustine 5Flucytosine 5Etoposide 5Thiotepa 4Sirolimus 4Cyclophosphamide 4aldesleukin 3Thalidomide 3Surveys and Questionnaires 3Sunitinib 3Radiotherapy, Intensity-Modulated 3Radiation 3Polymerase Chain Reaction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Oligodendroglioma × Dasatinib × Clear all
NCT00892177 2019-10-21

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme

Alliance for Clinical Trials in Oncology

Phase 2 Completed
144 enrolled 14 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡